41st week of 2009 patent applcation highlights part 33 |
Patent application number | Title | Published |
20090252734 | Antihuman alpha 9 Integrin Antibody and use of the Same - The present invention relates to: an antibody (particularly a monoclonal antibody), a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human α9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the human α9 integrin antibody; a method for screening a compound which inhibits the activity of human α9 integrin; and the like. | 2009-10-08 |
20090252735 | Novel Peptides for Development of Diagnostic and Therapeutic Agents and Methods of Using Same - Novel immuno-interactive fragments of the αC portion of a mammalian inhibin α subunit, together with their variants and derivatives, produce antigen-binding molecules that are interactive with the αC portion, and which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin. | 2009-10-08 |
20090252736 | Mammalian Genes; Related Reagents - Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. | 2009-10-08 |
20090252737 | T Cell Regulatory Genes And Methods Of Use Thereof - A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1. | 2009-10-08 |
20090252738 | Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix - Compositions and methods useful in inhibiting proliferation of CA IX+preneoplastic or neoplastic cells in a mammal are provided. The compositions are antagonist anti-CA IX antibodies and other inhibitory agents that target carbonic anhydrase activity of CA IX on these cells. The antagonist anti-CA IX antibodies or antigen-binding fragments thereof are specifically reactive with an inhibitory epitope of CA IX or biologically active variant thereof. Formation of an antibody-antigen complex between the antagonist anti-CA IX antibodies or antigen-binding fragments thereof and the respective inhibitory epitopes results in inhibition of carbonic anhydrase activity of CA IX or biologically active variant thereof. Other small molecule agents that inhibit carbonic anhydrase activity of CA IX or biologically active variant thereof and screening assays for identifying such agents are also provided. The antagonist anti-CA IX antibodies, antigen-binding fragments thereof, and other CA IX inhibitory agents identified herein are useful in the treatment of cancers characterized by the expression of the CA IX tumor-associated antigen. | 2009-10-08 |
20090252739 | Cerebral Infarction Suppressant - An objective of the present invention is to provide a suppressant for cerebral infarction occurred after long-term ischemia associated with actual cerebral infarction, and has fewer side effects. The cerebral infarction suppressant of the present invention is characterized in comprising an anti-HMGB1 monoclonal antibody as an active ingredient. | 2009-10-08 |
20090252740 | Method for Predicting Responsiveness to TNF Alpha Blocking Agents - The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNFα blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method. | 2009-10-08 |
20090252741 | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES IN CANCER TREATMENT - Although results from preclinical studies in animal models have proven the concept for use of anti-CTLA-4 antibodies in cancer immunotherapy, two major obstacles have hindered their successful application for human cancer therapy. First, the lack of in vitro correlates of the anti-tumor effect of the antibodies makes it difficult to screen for the most efficacious antibody by in vitro analysis. Second, significant autoimmune side-effects have been observed In a recent clinical trial. In order to address these two issues, we have generated human CTLA-4 gene knock-in mice and used them to compare a panel of anti-human CTLA-4 antibodies for their ability to induce tumor rejection and autoimmunity. Surprisingly, while all antibodies induced protection against cancer and demonstrated some autoimmune side effects, the antibody that induced the strongest protection also induced the least autoimmune side effects. These results demonstrate that autoimmune disease does not quantitatively correlate with cancer immunity. Our approach may be generally applicable to the development of human therapeutic antibodies. | 2009-10-08 |
20090252742 | IL3Ralpha antibody conjugates and uses thereof - The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα. | 2009-10-08 |
20090252743 | Anti-TNF Antibodies, Compositions, Methods and Uses - The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods. | 2009-10-08 |
20090252744 | Methods for Treating Bone Cancer Pain by Administering A Nerve Growth Factor Antagonist antibody - The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF. | 2009-10-08 |
20090252745 | Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis - The presently disclosed subject matter provides methods and compositions for predicting a tendency of a subject infected with hepatitis C virus (HCV) to develop steatosis. In some embodiments, the disclosed methods include the steps of (a) isolating from the subject a biological sample comprising an HCV Core polypeptide or a nucleic acid molecule encoding an HCV Core polypeptide; and (b) identifying the amino acids in the HCV Core polypeptide or encoded by the nucleic acid molecule in the biological sample corresponding to positions 182/186 of an HCV Core polypeptide amino acid sequence, whereby a tendency to develop steatosis in the subject is predicted when the amino acids corresponding to positions 182/186 of the HCV Core polypeptide amino acid sequence in the biological sample are either phenylalanine/valine or leucine/isoleucine. Also provided are compositions and methods for screening for candidate modulators of lipid accumulation in a subject as well as uses for the candidate modulators. | 2009-10-08 |
20090252746 | ERYTHROPOIETIN RECEPTOR BINDING ANTIBODIES - The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies. | 2009-10-08 |
20090252747 | NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 282P1G3 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization. | 2009-10-08 |
20090252748 | Sp35 Antibodies and Uses Thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody. | 2009-10-08 |
20090252749 | Compositions and Methods for Producing a Composition - The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig. | 2009-10-08 |
20090252750 | ANTIBODIES AND IMMUNOTOXINS THAT TARGET HUMAN GLYCOPROTEIN NMB - The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells. | 2009-10-08 |
20090252751 | Immune adjuvant comprising ubiquinone - This invention relates to an immunoadjuvant, which has an excellent antibody production enhancing function and is highly safe, and a vaccine composition comprising the immunoadjuvant. More specifically, the present invention relates to an immunoadjuvant comprising a ubiquinone represented by formula (I), and a vaccine composition comprising the ubiquinone represented by formula (I): | 2009-10-08 |
20090252752 | KDR PEPTIDES AND VACCINES COMPRISING THE SAME - The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines. | 2009-10-08 |
20090252753 | IMMUNOMODULATION FOR AUTOIMMUNE TYPE-2 DIABETES - The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant. | 2009-10-08 |
20090252754 | Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses - Tat, when used in a vaccine, causes MHC-I to expose subdominant epitopes present within an antigen, thereby enabling an optimal immune response to be generated, within an individual, against the antigen and variants of the antigen, such as might be encountered with HIV or influenza viruses. | 2009-10-08 |
20090252755 | CLONED GENOME OF INFECTIOUS HEPATITIS C VIRUS STRAIN HC-TN AND USES THEREOF - Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1 | 2009-10-08 |
20090252756 | PROTEIN-BASED STREPTOCOCCUS PNEUMONIAE VACCINES - Vaccine compositions and methods for protecting a mammalian subject against infection with | 2009-10-08 |
20090252757 | METHODS AND COMPOSITIONS FOR INHIBITING HIV INFECTION - This invention provides novel HIV-interacting host factors. The invention also provides methods of using the HIV-interacting host factors to screen for compounds that inhibit HIV infection. The methods comprise first screening test compounds for modulators of an HIV interacting host factor disclosed herein, and then further screening the identified modulating compounds for ability to inhibit HIV infection. The invention further provides methods and pharmaceutical compositions for treating diseases and conditions associated with HIV infection. | 2009-10-08 |
20090252758 | NUTRITIONAL SUPPLEMENT FOR THE PREVENTION OF CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE, DIABETES, AND REGULATION AND REDUCTION OF BLOOD SUGAR AND INSULIN RESISTANCE - A mixture is formulated that is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar using natural and synthetic ingredients. A mixture of the present invention may be used as a food, a drink, a supplement or potentially a drug. Numerous ratios of ingredients may be formulated to balance flow (viscosity), sediment/uniformity, color, taste, flavor and aroma. Moreover, a method of making certain ingredients soluble in water and/or oil by micro-emulsion and a method encapsulating key ingredient(s) in nano-vessel are described herein. | 2009-10-08 |
20090252759 | IMMUNOGENIC COMPOSITION - The present application relates to an immunogenic composition comprising at least 2 conjugates of | 2009-10-08 |
20090252760 | Construction of Recombinant Adenovirus With Genes That Codify for SAG1, SAG2 and SAG3 - This invention refers to the construction of recombinant adenovirus with genes that codify for | 2009-10-08 |
20090252761 | Papilloma virus vaccine - A method of providing papilloma virus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in relation to infections caused by papilloma virus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papilloma virus L1 protein or a combination of papilloma virus L1 protein and papilloma virus L2 protein followed by a further step of transfecting a suitable host cell with one or more of the recombinant DNA molecules so that virus like particles (VLPs) are produced within the cell after expression of the L1 or combination of L1 and L2 proteins. The VLPs are also claimed per se as well as vaccines incorporating the VLPs. | 2009-10-08 |
20090252762 | NOVEL PROTEOSOME-LIPOSACCHARIDE VACCINE ADJUVANT - An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols. | 2009-10-08 |
20090252763 | BIOLOGICAL ADJUVANTS - A method of enhancing uptake of DNA by a host cell line comprises introducing the DNA into the host cell and contacting the host cell with non-infectious viral particles. The non-infectious particles may be L-particle or PREPS (pre-viral DNA replication envelope particles), for example, those derived from alpha herpesvirus. | 2009-10-08 |
20090252764 | SUTURE LINE ADMINISTRATION TECHNIQUE USING BOTULINUM TOXIN - The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull. | 2009-10-08 |
20090252765 | BACILLE CALMETTE-GUERIN (BCG)-BASED ANTI-ATHEROMA VACCINE AND METHODS OF USE THEREOF - The invention relates to a recombinant | 2009-10-08 |
20090252766 | ATTENUATED GRAM NEGATIVE BACTERIA - Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed. | 2009-10-08 |
20090252767 | Water dispersible enteric coating formulation of nutraceutical and pharmaceutical dosage forms - The present invention relates to formulations for use as enteric coatings. More particularly, the present invention relates to a formulation comprising a dry blend of food grade ingredients that can be readily dispersed in water. This dispersion exhibits low viscosity and can easily be coated onto solid dosage forms through spraying and the like to provide an enteric coating on the solid dosage form. | 2009-10-08 |
20090252768 | USE OF STILBENE DERIVATIVES FOR TREATMENT AND PREVENTION OF AQUATIC MOLD INFECTIONS - The invention relates to methods of treatment and prevention of aquatic mold infections in aquatic organisms and methods of disinfecting equipment used in raising aquatic organisms. The methods comprise use of one or more stilbene derivatives, including 4,4′-bis-(1,3,5-triazinylamino)stilbene-2,2′-disulfonic acid derivatives. | 2009-10-08 |
20090252769 | PREVENTIVE AND THERAPEUTIC VACCINE FOR STORKE AND NEUROLOGICAL DISORDERS - A method for producing therapeutic vaccine which consist of NMDA-NR1 subunit expressed in insect cells to produce recombinant protein and was encapsulated in poly(D-L-lactide-co-glycolic-acid) (PGLA) microparticles by solvent exchange and used for oral immunization. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NR1 sub units, their protective and therapeutic potential for treatment of the neurological disorder of stroke in animals and its practicability for therapy in humans. | 2009-10-08 |
20090252770 | NON-DIGESTIBLE SUGAR-COATED PRODUCTS AND PROCESS - A method and composition are provided for coating a component to achieve colon-targeted delivery. A component is coated with a fructose-based non-digestible carbohydrate such as a inulin, fructo-oligosaccharide or neosugar. The coated component is orally administered to a monogastric animal. The non-digestible coating causes the composition to pass through the stomach and small intestine without being degraded, and delivers the component to the colon where the coating is digested by microbial fermentation and the component is released. | 2009-10-08 |
20090252771 | METHOD FOR OBTAINING O/W COSMETIC EMULSIONS WITH HIGH WATER RESISTANCE - This invention relates to a method for obtaining cationic O/W emulsions designed for skin care, which present high water resistance associated with excellent “skin feeling” characteristics. | 2009-10-08 |
20090252772 | PEARLESCENT PIGMENTS COATED WITH MIXED INORGANIC/ORGANIC LAYERS AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to platelet-shaped pearlescent pigments that are coated with at least one mixed inorganic/organic layer for improving their application properties, and of these, particularly their mechanical properties, and to methods for the production thereof and to the use thereof. The said mixed inorganic/organic layer comprises at least one at least partially crosslinked inorganic metal-oxide component and an organic component. The organic component is at least one organic oligomer and/or polymer, which is covalently bonded, at least in part, to the inorganic network via network formers, wherein the coating comprises at least one mixed inorganic/organic layer, which mixed layer comprises, at least in part, an inorganic network having one or more inorganic oxide component(s) and at least one organic component, the organic component being, at least in part, an organic oligomer and/or polymer covalently bonded, at least in part, to the inorganic network via one or more organic network formers. | 2009-10-08 |
20090252773 | EMULSION COMPOSITION - An emulsion composition of the present invention includes (A) a salt of a higher fatty acid ester of ascorbic acid-2-phosphoric acid ester, (B) a polyglycerin fatty acid monoester including polyglycerin having a mean polymerization degree of 8 to 12 and an unsaturated fatty acid residual group of 14 to 22 carbon atoms, (C) a polyglycerin fatty acid monoester comprising polyglycerin having a mean polymerization degree of 2 to 6 and an unsaturated fatty acid residual group of 14 to 22 carbon atoms, and (D) a hydrocarbon oil, wherein the blending ratio by mass between the component (B) and the component (C) is in the range of 1:1 to 3:1, and the blending ratio by mass between the total of the components (B) and (C) and the component (D) is in the range of 10:1 to 1:4. By the use of the emulsion composition of the present invention, a skin external preparation can be provided which is prevented from decrease of a salt of a higher fatty acid ester of ascorbic acid-2-phosphoric acid ester attributable to decomposition of the salt, is excellent in retention of moisture, and has a beautiful appearance. | 2009-10-08 |
20090252774 | POWDER SURFACE-TREATED WITH AN ORGANOPOLYSILOXANE HAVING CARBOXYL GROUPS, A DISPERSION OF THE SAME, AND A COSMETIC COMPRISING THE SAME - A powder surface-treated with an organopolysiloxane represented by the following average compositional formula (1): | 2009-10-08 |
20090252775 | VIRUCIDAL DISINFECTANT - A virucidal disinfectant having broad-range activity includes an acidic phosphorus compound and/or salt thereof, an alcohol, and one or more polyalkylene glycols. The disinfectant, which may also kill bacteria and/or fungi, may be used for the hygienic disinfection of animate and inanimate surfaces. The invention also provides a disinfection method and a product containing a disinfectant. | 2009-10-08 |
20090252776 | ANIMAL DETERRENT FOR PROTECTING PLANTS - The invention provides materials, compositions, methods, and kits for deterring or repelling animals from eating plant materials. The invention relates to the use of particulate matter to deter animals from eating plant materials that are susceptible to grazing by animals. In exemplary embodiments, an adhesive is applied to target plant material and the particulate matter is then applied prior to curing or drying of the adhesive. | 2009-10-08 |
20090252777 | Method for formulating a controlled-release pharmaceutical formulation - Methods for making formulations of drugs and crystalline side chain polymers which formulations provide controlled and/or sustained release drug formulations. | 2009-10-08 |
20090252778 | METHODS AND DEVICES FOR REDUCING TISSUE DAMAGE AFTER ISCHEMIC INJURY - Methods and devices are provided for the delivery of therapeutic agents which reduce myocardial tissue damage due to ischemia and anti-restenotic agents which inhibit restenosis following a cardiac procedure such as stent implantation. The anti-ischemia agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction in ischemic or reperfusion injury of the myocardial tissue. The anti-restenotic agents are delivered over an administration period sufficient to reduce the re-narrowing of a blood vessel following a cardiac procedure such as implantation of a device. Preferred anti-restenotic drugs are those that do not reduce the beneficial effects provided by the anti-ischemic drug, such as drugs that do not act on the mammalian target of rapamycin (mTOR). | 2009-10-08 |
20090252779 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists. | 2009-10-08 |
20090252780 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES - Coatings for implantable medical devices comprising non-fouling moieties or polymers chemically bonded to the surface of the device via chelating structures, and methods of fabricating the coatings are disclosed. | 2009-10-08 |
20090252781 | HYDROGEL POLYMERIC COMPOSITIONS AND METHODS - Some aspects of this disclosure relate to a method of treating an opthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent. | 2009-10-08 |
20090252782 | Transdermal Preparations Containing Hydrophoic Non-Steroidal Anti-Inflammatory Drugs - Disclosed is a transdermal preparation containing a hydrophobic drug. As a method of continuing the high drug permeation, it is used an unique hydrophilic polymer system in which the drug can be contained in a high concentration under no water environment, a solubility of the hydrophobic drug is decreased as the water is introduced to the patch from the skin, so that the drug is maintained at the saturation concentration even though the drug content is decreased as the drug is permeated to the skin. During the application of the transdermal preparation to the skin, it is possible to continuously permeate the high amount of drug, to maintain the sufficient adhesion during the use and to minimize the skin side effect, because the hydrophilic polymer absorbs the water from the skin. The hydrophilic polymer system can serve the function thereof through the hydrophobic adhesive layer capable of preventing the water quickly absorbed from the skin from being evaporated to the outside of the patch. | 2009-10-08 |
20090252783 | MEANS FOR INHIBITING THE EXPRESSION OF CD31 - The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ ID NO: 1, whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1277 to 1295 of SEQ ID NO: 1; from nucleotide positions 2140 to 2158 of SEQ ID NO:1; from nucleotide positions 2391 to 2409 of SEQ ID NO: 1; and whereby the first stretch is additionally at least partially complementary to a region preceding the 5′ end of the nucleotide core sequence and/or to a region following the 3′ end of the nucleotide core sequence. | 2009-10-08 |
20090252784 | Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same - Compositions for inhibiting RNA binding proteins, as well as methods of producing and using the same, are disclosed herein. | 2009-10-08 |
20090252785 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES - Provided are compositions that include lipid particles, such as liposomes, that can fuse with the ER membrane of a cell. The lipid particles can also deliver a cargo, such as a therapeutic or an imaging agent, encapsulated inside the particles inside the ER lumen of the cell. The compositions can be useful for treating and/or preventing diseases or conditions caused by or associated with a virus, such as viral infections, including HIV and HCV infections. | 2009-10-08 |
20090252786 | Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor - The present invention relates to a method of preventing or treating in a subject a disorder characterized in a reduced GABA receptor function by administering to the subject a therapeutically effective amount of a pharmacologically active blood serum product obtainable by a method comprising electrostimulation of a non-human animal, withdrawal of blood from said animal isolation of serum from said blood, and gamma irradiation of said serum. | 2009-10-08 |
20090252787 | GRANULAR PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient. | 2009-10-08 |
20090252788 | Balsalazide formulations and manufacture and use thereof - The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide. | 2009-10-08 |
20090252789 | ONE STEP SPRAY-DRYING PROCESS - Capsules encapsulating an active or functional ingredient are obtainable by a process in which a feed that includes this ingredient is dispersed in the form of drops in a spraying tower and exposed to a temperature in the range of −20° C. to 500° C. In the tower, a cloud of suspended powdering agent provides a coating and prevents the capsules from sticking together and a reactant is provided to react with a polymer or film-forming carrier of the active ingredient so as to modify the water solution properties of the capsule walls. | 2009-10-08 |
20090252790 | TABLET FORMULATION - The present invention relates to a pharmaceutical fixed dose combination tablet comprising repaglinide and metformin. The present invention also provides a method of producing said tablet. | 2009-10-08 |
20090252791 | PHARMACEUTICAL COMPOSITIONS COMPRISING A TRIPTAN AND A NONSTEROIDAL ANTI-INFLAMMATORY DRUG - Dosage forms for administering a triptan and a nonsteroidal anti-inflammatory drug are disclosed, including multilayered tablets and mini-tablets. These multilayered tablets can be in a side-by-side arrangement, can be inlayed, or one layer can completely surround another. These can be administered in a capsule or directly. Other formulations are also disclosed. | 2009-10-08 |
20090252792 | METHOD TO REDUCE THE SYMPTOMS OF HEARTBURN AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD) BY SPECIFIC POLYSACCHARIDES - The invention is directed to the use of a specific group of polysaccharides for reducing the symptoms or heartburn and gastroesophageal reflux isease. In addition, a pharmaceutical preparation is provided comprising a specific group of polysaccharides having a high hydration rate, a high viscosity, and a high stability at low pH. Such a preparation is particularly effective in reducing the symptoms of heartburn and/or gastro-oesophageal reflux disease, particularly when consumed in dry form. | 2009-10-08 |
20090252793 | PHARMACEUTICAL COMPOSITIONS - Oral dosage forms comprising oxcarbazepine which when administered to a patient display no food effect. | 2009-10-08 |
20090252794 | TABLET - The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by colestimide as an active ingredient, and has a visibility-resolved tablet edge. | 2009-10-08 |
20090252795 | Bioceramic scaffolds for tissue engineering - This invention relates to bioinert microporous bioceramic scaffolding, matrices or spheres comprising a particulate microporous bioinert ceramic material, which is a primary structure, and in the form of scaffolds, matrices or spheres, having interconnected pores. Pores on the surface of the spheres, matrices or scaffolds are connected to pores inside the spheres, matrices or scaffolds via blow-holes and the internal pores are in turn interconnected, so that in addition to a high porosity, the spheres, matrices or scaffolds will provide for a highly permeable, biosupportive environment for organic and/or inorganic substances, gases and/or liquids. The pores on the surface of the spheres, matrices or scaffolds are connected to pores inside the spheres, matrices or scaffolds via blow-holes and the internal interconnected pores within the highly porous microarchitecture or nanostructure(s) of the spheres, matrices or scaffolds will therefore prove conducive too, complimentary or suitable for, hosting such organic and/or inorganic substances, nanotechnologies, nanomaterials, gases or liquid that may be introduced, impregnated, activated, mixed, coated, transmitted or blended; and those various substances may be: resorbable bioceramic, polymers, copolymers, adhesives, hydrogels, collagen based materials, carbon based materials, metals, minerals, alternate corundum based materials, nanotechnologies, various forms of therapeutic energy, as well as various chemicals, chemoattractors and pharmaceutical agents or vaccine materials suitable for tissue treatment, tissue engineering, healing, regeneration/integration or repair of tissues within the body in order to ultimately restore tissue integrity, stability, viability, vitality, volume, mass, density, support, strength, purpose, design and function(s). | 2009-10-08 |
20090252796 | NUTRITIONAL SUPPLEMENT FOR THE PREVENTION OF CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE, DIABETES, AND REGULATION AND REDUCTION OF BLOOD SUGAR AND INSULIN RESISTANCE - A mixture (which may be utilized as a food or a drink or a supplement or a drug or a cosmetic or a hygienic product) that is formulated and is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar using natural and synthetic ingredients. Numerous ratios of ingredients may be formulated to balance synergy resonance of antioxidants, flow (viscosity), sediment/uniformity, color, taste, sugar content, flavor and aroma. Moreover, ingredients for natural preservatives and sugar substitutes and methods of nano-dispersion, nano-encapsulation, time-released delivery and apparatus for personalized nutrition are also described herein. | 2009-10-08 |
20090252797 | TOPICAL APPLICATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS/AFFLICTIONS - Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin. | 2009-10-08 |
20090252798 | MATRIX-GEL GRAFT WITHOUT CELLS - A cell-free graft contains (i) a cohesive, scaffold-forming matrix with open porosity containing a biologically and pharmaceutically acceptable material, and (ii) a gel of a biologically and pharmaceutically acceptable material. The cell-free graft is produced by (v) contacting the matrix with the gel, and (vi) drying the matrix-gel complex formed in (v). The cell-free graft can be used for covering and increasing the viscoelasticity of defects, for tissue regeneration and in particular for regenerating mesenchymal tissue, especially cartilage and/or bone. | 2009-10-08 |
20090252799 | MATERIALS AND METHODS FOR WOUND TREATMENT - The subject invention pertains to materials and methods for stopping or decreasing the blood flow from an open wound or medical or surgical procedure. Compositions of the invention comprise a salt form of a cross-linked polyacrylic acid. In one embodiment, the composition comprises a sodium salt of a polyacrylic acid. Compositions of the invention can also optionally comprise one or more different salt ferrates, and/or a cationic exchanger resins, and/or a silver compound. In an exemplified embodiment, a composition of the invention comprises sodium polyacrylate provided in a dry powdered form. Polyacrylate compositions of the invention can be applied directly to a wound or treatment site, or they can be incorporated into a wound dressing, such as a bandage. The clot or scab formed at a wound or treatment site treated with the present invention is extremely elastic and exhibits considerable tensile strength when stretched to the breaking point. The subject invention also concerns wound and surgical site dressings and coverings, and methods of using a composition of the invention to stop blood flow from an open wound or treatment site. | 2009-10-08 |
20090252800 | Anisotropic nanocomposite hydrogel - Anisotropic nanocomposite hydrogel materials are created using a process in which a hydrogel-forming material is crosslinked in the presence of nanoscale cellulose and subsequently thermally cycled under an applied tensile strain. Such materials are capable of exhibiting high mechanical and viscoelastic anisotropy, increased stiffness when subjected to large strain, and are suitable for a broad range of soft tissue replacement applications. In addition controlled release of bioactive agents properties can be designed into medical devices fabricated from such nanocomposite materials. | 2009-10-08 |
20090252801 | Process for the Preparation of Micronised Sterile Steroids - The present invention relates to a process for the preparation of micronised sterile steroids, comprising sterilisation of the steroids in crystalline form by means of irradiation with gamma or beta rays, and subsequent sterile micronisation. | 2009-10-08 |
20090252802 | Compositions Including Relatively Water Insoluble/Unwettable Drugs And Methods For Using Same - Compositions including therapeutic components and surfactant components which enhance the utility of the therapeutic components and methods of using such compositions are provided. | 2009-10-08 |
20090252803 | GLYCYRRHETINIC ACID-MEDIATED NANOPARTICLES OF HEPATIC TARGETED DRUG DELIVERY SYSTEM, PROCESS FOR PREPARING THE SAME AND USE THEREOF - Disclosed are a hepatic targeted drug delivery system and a process for preparing the same. Also disclosed is a method for treating liver cancer. | 2009-10-08 |
20090252804 | MEDICAL DEVICES WITH AN ANTIBACTERIAL POLYURETHANEUREA COATING - The present invention relates to a medical device which has at least one coating which is obtained starting from an aqueous dispersion, the aqueous dispersion comprising at least one nonionically stabilized polyurethaneurea and at least one silver-containing constituent. | 2009-10-08 |
20090252805 | Film-Coated and/or Granulated Calcium-Containing Compounds and Use Thereof in Pharmaceutical Compositions - Calcium-containing compounds have been at least partly film-coated and/or granulated with a water-soluble substance and a water-soluble polymeric substance and use of such coated compounds in pharmaceutical compositions. The at least partly film-coated and/or granulated calcium-containing compounds have proved suitable for the preparation of tablets having a very high load of elemental calcium and a conveniently small size. A drug load of about 96% or more is obtained in tablets of the invention that have sufficient mechanical and organoleptic properties. | 2009-10-08 |
20090252806 | NANOPARTICULATE TACROLIMUS FORMULATIONS - The present invention is directed to nanoparticulate tacrolimus compositions. The composition comprising tacrolimus particles having an effective average particle size of less than about 2000 nm and at least one surface stabilizer. | 2009-10-08 |
20090252807 | Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives - The present invention is directed to compositions comprising a nanoparticulate prostaglandin derivative, preferably limaprost or a salt or derivative thereof, having improved bioavailability. The nanoparticulate prostaglandin derivative particles of the composition have an effective average particles size of less than about 2000 nm and are useful in the treatment of ischemic symptoms. The invention also relates to a controlled release composition comprising a prostaglandin derivative, such as limaprost alfadex, or a nanoparticulate prostaglandin derivative, such as limaprost or a salt or derivative thereof, that in operation delivers the drug in a pulsed or bimodal manner for the treatment of ischemic symptoms. | 2009-10-08 |
20090252808 | CONTROLLED RELEASE OF BIOLOGICAL ENTITIES - A process is provided for releasably encapsulating a biological entity. The process comprise combining a solution of a surfactant in a non-polar solvent with a precursor material and the biological entity to form an emulsion. The emulsion comprises a polar phase dispersed in a non-polar phase, wherein the polar phase comprises the biological entity. The particles comprising the biological entity are then formed from the polar phase. | 2009-10-08 |
20090252809 | Microcapsules From Emulsion Polymerization of Tetraalkoxysilane - A process is disclosed for preparing microcapsules having a shell thickness of at least 18 nanometers by polymerizing a tetraalkoxysilane at the oil/water interface of an emulsion containing 0.1 to 0.3 weight percent of a cationic surfactant. The microcapsules are useful to prepare encapsulated sunscreens having sufficient robustness to prevent leakage of the encapsulated sunscreen in a formulated composition. | 2009-10-08 |
20090252810 | Aryl/alkyl Succinic Anhydride-Hyaluronan Derivatives - The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties that can be used for advanced formulation (bind stronger to the skin compared to non-modified HA), possibly also in delivery systems for actives or drugs by encapsulation (nano/micro capsules) or formation of nano/micro spheres. Further, the low MW ASA-HA derivatives are expected to penetrate the skin more efficiently than non-modified HA of the same MW. | 2009-10-08 |
20090252811 | CAPPED MESOPOROUS SILICATES - The invention provides an article comprising, a mesoporous silicate matrix, such as a particle, having one or more pores; and one or more releasable caps obstructing one or more of the pores. The articles are useful as delivery vehicles for encapsulated agents such as therapeutic agents, polynucleotides, polypeptides and the like. | 2009-10-08 |
20090252812 | Use of Fermented Milk Product for Skin Treatment - The use of a fermented milk product comprising non-hydrolysed whey proteins which is substantially free of casein proteins for the purpose of improving skin firmness, by structuring collagen without promoting collagen synthesis, when topically applied to skin is provided. | 2009-10-08 |
20090252813 | CerCan: an energy supplement product for boosting the immune system - This invention concerns the process of creating an energy supplement product, good also as an anti-aging, aphrodisiac and as an alternative source to prevent or to remedy some diseases. The product is a composition of five ingredients: four marine animals (sea cucumber, sea urchin, sea sponge, and shark fin), and an algae called Sargassum. These ingredients are sterilized and then dried by using isothermal isotopes, reduced to powder, measured and encapsulated. | 2009-10-08 |
20090252814 | USE OF XENON FOR ORGAN PROTECTION - Use of xenon is described. Xenon is used as an organ and/or tissue and/or cell protectant in the manufacture of a pharmaceutical for the protection from injury of organs and/or tissue and/or cells that express HIF. | 2009-10-08 |
20090252815 | Pulverulent mixtures containing hydrogen peroxide and hydrophobized silicon dioxide - The present invention is directed to pulverulent mixtures comprising hydrogen peroxide and hydrophobized, pyrogenically prepared silicon dioxide powder, preferably with a methanol wettability of at least 40. The pulverulent mixtures exhibit good storage stability and can be used for the controlled release of hydrogen peroxide and/or oxygen. The invention also includes methods of making these pulverulent mixtures and methods of using the mixtures in detergents, cleaning compositions, topical medications, antimicrobials and other products. | 2009-10-08 |
20090252816 | Inhalable Gaseous Medicament Based On Xenon And Nitrous Oxide - The invention concerns the use of a gaseous mixture containing gas xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for preventing or treating neurointoxication in a human. The xenon/nitrous oxide mixture of the invention acts on one or more cerebral receptors to reduce the release and/or the effects of dopamine, glutamate, serotonin, taurin, GABA, noradrenaline and/or any other neurotransmitter. The proportion by volume of xenon of the mixture ranges between 5 and 45%, and the proportion by volume of nitrous oxide ranges between 10 and 50%, the balance is preferably oxygen. | 2009-10-08 |
20090252817 | Methods for the treatment or prevention of Diabetes Mellitus and other metabolic imbalances - The invention relates to methods for treatment and prevention of a metabolic imbalance, including diabetes mellitus and other related diseases or disorders, using an extract from a fruit of genus | 2009-10-08 |
20090252818 | Curcuma longa (turmeric) based herbal compound formulations as dietary supplements - Herbal compound formulations using herbs | 2009-10-08 |
20090252819 | BLOWN FILM EXTRUSION DEVICE - The invention describes a blown film extrusion device with a blow head ( | 2009-10-08 |
20090252820 | COMBINATION SCOOP AND MOLD PRESS FOR DOUGH FISHING BAIT - A combination scoop and mold press includes two generally cup-shaped half-mold members, which engage one another at mold member edges in mirror-image alignment to form a generally enclosed mold. The half-mold members of the scoop and mold press are carried on opposite ends of a unitary piece of injection molded polymeric material, which has a live hinge joint equidistantly spaced between the mold members. Either of the half-mold members may be utilized to scoop out an appropriate mass of bait dough having at least the volume of the closed mold. At least one of the half-mold members is equipped with a notch or slit through which the shank of a fish hook, or the line which is tied to the fish hook, may pass. Finger pressure is used to bring the mold half-members together, compressing the bait dough around the hook. | 2009-10-08 |
20090252821 | METHOD AND APPARATUS FOR FABRICATING THREE DIMENSIONAL MODELS - An apparatus and method for fabricating a three dimensional model from a composite model formed or a plurality of successive layers of model material and sacrificial mold material. Each successive layer is constructed by depositing, drop-by-drop, at least one line of sacrifical mold material delineating at least one boundary of the model material within the layer and thereafter depositing the model material onto all delineated regions of the layer by spray deposition. Each successive layer is completed by a planing process which removes the undesired thickness of both the sacrificial and the model materials. Following completion of the composite model, the sacrificial mold material is removable from the composite model, by a process effecting only the sacrificial mold material, to produce the three dimensional model. A device, for depositing the model material at the rate faster than the rate that the mold material is deposited, is also described. | 2009-10-08 |
20090252822 | Snow Ball Forming Apparatus - Disclosed is a snow ball forming apparatus for forming snow balls. The snow ball forming apparatus includes a first elongated member, a second elongated member, an attachment means, a first hemispherical cup and a second hemispherical cup. The first and the second elongated members have a top end portion, a bottom end portion, and an inner surface and an outer surface extending between the top end portion and the bottom end portion. The attachment means hingedly couples the first and the second elongated members. Each of the first and the second hemispherical cups are configured at the top end portions of the first and the second elongated members, respectively, and comprise a cavity adapted to receive snow configured therein. The first and the second hemispherical cups may be moved towards each other to form a snow ball from the snow received in the cavity thereof. | 2009-10-08 |
20090252823 | ROTOR FOR A ROTARY TABLET PRESS - A rotor for a rotary tablet press, which has an upper and a lower punch guide for upper and lower punches that interact with holes in a die plate that is arranged between the upper and lower punch guide, where the punches are axially movable in guide holes of the punch guides and have heads that interact with compression rollers of the tablet press, wherein the press punches are guided axially in the guide holes secure against rotation, and the punch heads have on opposite sides flat areas that are facing the adjacent punch heads. | 2009-10-08 |
20090252824 | DOUGH MOULDER - A dough moulder including a dough conveyor operable to receive a strip of dough, the conveyor having a first run operable to co-operate with a curling element to curl or roll the dough strip into a dough piece and a second run operable with a pressure rolling board to mould the dough piece, wherein the pressure rolling board has an upper section and a lower section, the lower section including a plurality of formed channels or troughs. | 2009-10-08 |
20090252825 | Antireflective member, optical element, display device, method of making stamper and method of making antireflective member using the stamper - An antireflective member according to the present invention has an uneven surface pattern, in which unit structures are arranged in x and y directions at respective periods that are both shorter than the shortest wavelength of an incoming light ray, on the surface of a substrate and satisfies the following Inequality (1): | 2009-10-08 |
20090252826 | INJECTION MOLDING MACHINE - An injection molding machine includes supporting plates, molds coupled to the supporting plates, and a coupling guide device to guide the coupling of the molds and the supporting plates. The coupling guide device includes a first coupling guide recess and a first coupling guide protrusion provided at center portions of the molds and the supporting plates so as to be coupled to each other, and a second coupling guide recess and a second coupling guide protrusion provided at the molds and the supporting plates, spaced apart from the first coupling guide recess and the first coupling guide protrusion, so as to be coupled to each other. The second coupling guide recess is formed lengthwise in a direction toward a periphery from the center portions of the molds and the supporting plates. | 2009-10-08 |
20090252827 | Horse feed and methods of treating horses - A horse feed mixture and method of treating a horse is disclosed. Feed mixtures disclosed contains more than 15% spelt, vegetable oil and vitamins and have less than 20% by weight fillers and less than 5% by weight sugar. The feed may be used to treat ailments including underweight condition, founder, colic, obesity, ulcers, inflammation, and chronic disease. | 2009-10-08 |
20090252828 | ALPHA-AMYLASE VARIANTS WITH ALTERED PROPERTIES - Disclosed are compositions comprising variants of alpha-amylase that have alpha-amylase activity and which exhibit altered properties relative to a parent AmyS-like alpha-amylase from which they are derived. The compositions comprise an additional enzyme such as a phytase. Also disclosed are methods of using the compositions, and kits related thereto. | 2009-10-08 |
20090252829 | BREWING VINEGAR AND IT'S MANUFACTURING METHOD - The brewing vinegar produced by zymolysis and alcohol fermentation in the bean jam particle of sloppy legumes such as adzuki bean in paraellel, and subsequently its acetic acid fermentation and its manufacturing method. By this manufacturing method the alcohol fermentation in the product by zymolysis is performed immediately, which shows the effective prevention of corruption by pest bacteria. Brewing vinegar containing abundant polyphenol is produced by the acetic acid fermentation performed sequentially. | 2009-10-08 |
20090252830 | Process of producing probiotic enhanced brown rice bran nutritional suppliment to promote increased levels of intestinal flora - The present invention is a pulverized fiber composition manufactured through fermentation of Brown Rice Bran with Lactobacillus Bulgaricus bacteria, which is enhanced with Bifidus and Acidophilus, resulting in a cereal with beneficial health properties; where, the fiber can be used as a natural dietary supplement and medicaments for the treatment and prevention of Gastrointestinal disorder, yeast infection, skin disorder, and hair thinning by boosting levels of beneficial intestinal flora which aid in digestion and boosts the human immune system. | 2009-10-08 |
20090252831 | PROCESS FOR MANUFACTURING A FERMENTED MILK - The invention relates to a manufacturing process of stirred or drinking fermented milk or fresh cheese comprising a smoothing step after fermentation wherein said smoothing step is performed by a ring-shaped rotor-stator mixer, each ring of the rotor and the stator being provided with radial slots having a given width, and adjusting the rotational speed to adjust the peripheral velocity. | 2009-10-08 |
20090252832 | Method and Apparatus for Producing Cooked Bacon Using Starter Cultures - A method for preparing cooked particulate meat products using a starter culture, such as bacon bits or other bacon seasonings and toppings. The raw meat is ground to a first size in a first grinder, mixed with dry cure which includes a starter culture to form a raw meat mixture, cooled, and stored long enough to allow for partial fermentation. The raw meat mixture is then ground and diced to a second size in a first dicer, evenly spread onto a cooking belt, cooked in one or more continuous cooking ovens to form a cooked meat mixture and diced again to a third size in a second dicer. | 2009-10-08 |
20090252833 | RUMINANT FEEDSTOCK DIETARY SUPPLEMENT - This invention provides a control release formulation or rumen-bypass dietary supplement in compacted form. The formulation or supplement has the capability to transport fatty acid calcium salt and between about 1-75 percent of one or more rumen-protected undegraded biologically active agents to the post-ruminal digestive system of a ruminant. A feedstock containing the formulation or supplement for ruminants beneficially improves feed efficiency and body growth. The feedstock also is adapted to improve the lactational performance of dairy cattle. | 2009-10-08 |